GLP-1 drugs for kids: what the pediatric obesity trials actually show

What's this video probably claiming?

Based on the caption, @earnyourleisure appears to be covering pharmaceutical expansion of GLP-1 and related weight-loss drugs into pediatric populations. The likely framing: Eli Lilly is eyeing tirzepatide (Mounjaro) trials in children as young as six with obesity diagnoses, while Novo Nordisk is assessing liraglutide (Saxenda) for younger age groups. Given the channel's finance-and-business angle, the video probably frames this as a market opportunity story, not a clinical one. That context matters. Business creators covering drug pipelines tend to compress regulatory nuance, conflate "exploring trials" with "approved treatment," and skip the part where pediatric pharmacology is genuinely complicated. The claim that these companies are "considering" or "evaluating" these drugs for children is broadly accurate as a headline, but the details underneath that headline deserve serious scrutiny before anyone walks away thinking these treatments are ready or routine for six-year-olds.

What does the science actually show?

Pediatric GLP-1 data exists, but it is thin and age-stratified in ways that matter. The most solid evidence base is for liraglutide (Saxenda) in adolescents 12 and older: the SCALE Teens trial (Kelly et al., 2020, New England Journal of Medicine) showed a 5.0 kg/m2 reduction in BMI versus 1.6 kg/m2 for placebo over 56 weeks in 251 adolescents with obesity. That is meaningful. For semaglutide, a 2022 phase 3 trial (Weghuber et al., NEJM) demonstrated a 16.1% reduction in BMI among adolescents 12-17. Tirzepatide, however, has no published pediatric efficacy data as of mid-2025. Eli Lilly has registered trials for tirzepatide in children, but "registered" is not "completed" and it is definitely not "approved." For children under 12, the data is essentially nonexistent for any GLP-1 agent. Long-term effects on growth, bone density, and pubertal development in this population remain unstudied.

Where does the social media noise diverge from clinical reality?

The gap between "pharma is exploring this" and "this is a viable treatment for six-year-olds" is enormous, and social media consistently collapses it. A few specific distortions to watch for in this content category. First, Mounjaro is a diabetes drug. It is not FDA-approved for weight management in adults under that brand name (Zepbound is). Calling it a "weight-loss treatment" for children blurs an already complicated regulatory picture. Second, Saxenda does have FDA approval for adolescents 12 and older, but the caption implies evaluation for younger ages, which is a different regulatory and ethical conversation entirely. Third, framing this purely as pharmaceutical ambition ignores that the American Academy of Pediatrics updated its obesity guidelines in 2023 to include pharmacotherapy as an earlier intervention option, which is actually the clinical driver behind some of this pipeline interest. The business lens misses the clinical context almost entirely.

What should you actually know?

If you are a parent, clinician, or just someone trying to parse this topic honestly, here is what the current evidence supports. Liraglutide (Saxenda) is the only GLP-1 agent with FDA approval specifically for weight management in adolescents, and that approval covers ages 12 and up at 3.0 mg daily. Semaglutide (Wegovy) received FDA approval for adolescents 12 and older in December 2022. Neither drug has approval for children under 12 for obesity. Tirzepatide trials in pediatric populations are ongoing but unpublished. The 2023 AAP clinical practice guidelines (Hampl et al., Pediatrics) do recommend offering pharmacotherapy alongside behavioral intervention for adolescents with obesity, which represents a real shift from prior "watchful waiting" approaches. That context is what is actually driving pipeline expansion. Any video that skips the regulatory approval status, the age cutoffs, and the evidence gaps is giving you an incomplete picture, regardless of how confident it sounds.